NCT02339129View on ClinicalTrials.gov

Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

February 28, 2015

Study Completion Date

March 31, 2015

Conditions
Delayed Onset Muscle Soreness
Interventions
DRUG

SST-0225

SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.

DRUG

Placebo

Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.

Trial Locations (2)

33143

Site #201, South Miami

65802

Site #202, Springfield

All Listed Sponsors
lead

Strategic Science & Technologies, LLC

INDUSTRY

NCT02339129 - Dosing Interval Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness | Biotech Hunter | Biotech Hunter